AR045728A1 - Composiciones de un inhibidor de catepsina k y un bifosfonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor - Google Patents

Composiciones de un inhibidor de catepsina k y un bifosfonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor

Info

Publication number
AR045728A1
AR045728A1 ARP040102560A ARP040102560A AR045728A1 AR 045728 A1 AR045728 A1 AR 045728A1 AR P040102560 A ARP040102560 A AR P040102560A AR P040102560 A ARP040102560 A AR P040102560A AR 045728 A1 AR045728 A1 AR 045728A1
Authority
AR
Argentina
Prior art keywords
osea
tumor
treatment
bifosphonate
catepsin
Prior art date
Application number
ARP040102560A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135094&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045728(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR045728A1 publication Critical patent/AR045728A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparaciones farmacéuticas que comprenden ciertos tipos de bisfosfonatos, como por ejemplo ácido zoleprónico, entre otros, y ciertos tipos de inhibidores de Catepsina K, como por ejemplo, N-[1-(cianometil-cambamoil)-ciclohexil]-4-(4-(1-propil)- piperazin-1-il)benzamida o sus sales farmacéuticamente aceptables, entre otros, en particular en la prevención y tratamiento de metástasis ósea, hipercalcemia inducida por tumor, crecimiento de tumor, pérdida ósea inducida por tumor y enfermedades de pérdida ósea tal como osteoporosis o pérdida ósea inducida por terapia de cáncer.
ARP040102560A 2003-07-21 2004-07-20 Composiciones de un inhibidor de catepsina k y un bifosfonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor AR045728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48892503P 2003-07-21 2003-07-21

Publications (1)

Publication Number Publication Date
AR045728A1 true AR045728A1 (es) 2005-11-09

Family

ID=34135094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102560A AR045728A1 (es) 2003-07-21 2004-07-20 Composiciones de un inhibidor de catepsina k y un bifosfonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor

Country Status (21)

Country Link
US (1) US20060281714A1 (es)
EP (1) EP1651238A1 (es)
JP (1) JP2006528151A (es)
KR (1) KR20060037382A (es)
CN (1) CN100406016C (es)
AR (1) AR045728A1 (es)
AU (1) AU2004262903B2 (es)
BR (1) BRPI0412769A (es)
CA (1) CA2532948A1 (es)
CO (1) CO5680441A2 (es)
EC (1) ECSP066293A (es)
IL (1) IL172913A0 (es)
IS (1) IS8311A (es)
MA (1) MA27925A1 (es)
MX (1) MXPA06000790A (es)
NO (1) NO20060851L (es)
PE (1) PE20050328A1 (es)
RU (1) RU2006105100A (es)
TN (1) TNSN06021A1 (es)
TW (1) TW200510436A (es)
WO (1) WO2005014006A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1686995A1 (en) * 2003-11-19 2006-08-09 Novartis AG Use of cathepsin k inhibitors for treating of severe bone loss diseases
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
EP1931994A2 (en) * 2005-09-26 2008-06-18 Novartis AG Molecular markers associated with bone metastasis
EP2216047A4 (en) * 2007-10-24 2011-12-28 Nat Univ Corp Tokyo Med & Dent REGULATOR FOR SIGNALING THE TOLL LIKE RECEPTOR WITH A CATHEPSIN INHIBITOR AS AN ACTIVE SUBSTANCE
EP3426674A4 (en) 2016-03-09 2019-08-14 Blade Therapeutics, Inc. CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2018009417A1 (en) 2016-07-05 2018-01-11 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018064119A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2020002565A1 (en) 2018-06-27 2020-01-02 Sabine Bauer Implants for recruiting and removing circulating tumor cells
EP4076271A2 (en) 2019-12-17 2022-10-26 Cirlo GmbH Tubular shaped elongated catheter device for interacting with components of bodily fluids
WO2023212104A1 (en) * 2022-04-27 2023-11-02 The Regents Of The University Of California Methods and agents for preventing skeletal aging, osteoporosis and obesity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501969A (en) * 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
US6544767B1 (en) * 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
CA2338275A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
US6506733B1 (en) * 1999-03-15 2003-01-14 Axys Pharmaceuticals, Inc. Compounds and compositions as protease inhibitors
JP2003500352A (ja) * 1999-05-21 2003-01-07 ノバルティス アクチエンゲゼルシャフト 血管形成を処置するためのビスホスホン酸の使用
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
ATE387197T1 (de) * 2001-11-13 2008-03-15 Merck Frosst Canada Ltd Cyanoalkylamino-derivate als protease-hemmer

Also Published As

Publication number Publication date
CO5680441A2 (es) 2006-09-29
NO20060851L (no) 2006-04-21
AU2004262903A1 (en) 2005-02-17
PE20050328A1 (es) 2005-06-16
AU2004262903B2 (en) 2007-08-23
JP2006528151A (ja) 2006-12-14
IL172913A0 (en) 2006-06-11
EP1651238A1 (en) 2006-05-03
US20060281714A1 (en) 2006-12-14
CN1826124A (zh) 2006-08-30
RU2006105100A (ru) 2007-09-20
TW200510436A (en) 2005-03-16
WO2005014006A1 (en) 2005-02-17
KR20060037382A (ko) 2006-05-03
CN100406016C (zh) 2008-07-30
BRPI0412769A (pt) 2006-09-26
IS8311A (is) 2006-02-17
TNSN06021A1 (en) 2007-10-03
CA2532948A1 (en) 2005-02-17
MXPA06000790A (es) 2006-04-07
ECSP066293A (es) 2006-07-28
MA27925A1 (fr) 2006-06-01

Similar Documents

Publication Publication Date Title
UY26625A1 (es) Inhibidores de proteasas
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
UY27558A1 (es) Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulación
CY1109422T1 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
NZ526913A (en) Inhibitors of cruzipain and other cysteine proteases
AR045728A1 (es) Composiciones de un inhibidor de catepsina k y un bifosfonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor
DE60313624D1 (de) Derivate von heteroarylnitrilverbindungen
TR200101869T2 (tr) Proteaz İnhibitörleri.
BR0212226A (pt) Pirrolo pirimidinas como agentes para inibição de cisteìna proteases
AR026173A1 (es) Inhibidores de neuraminidasas.
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
NO20044207L (no) Katepsin som cysteinproteaseinbibitorer
BRPI0517035A (pt) novos compostos
CY1110450T1 (el) Χρησιμοποιηση ενος παραγωγου αλογονιδιου υδροξιμικου οξεος στη θεραπευτικη αγωγη νευροεκφυλιστικων νοσων
UY27700A1 (es) Compuestos oxo - azabiclícos.
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
CO2024006279A2 (es) Inhibidores de molécula pequeña de proteasa específica de ubiquitina 1 (usp1) y usos de los mismos
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
ATE438618T1 (de) Inhibitoren von humanem adam-10
BRPI0410663A (pt) compostos de hidroxiamidina e hidroxiguanidina como inibidores de uroquinase
CO2024006269A2 (es) Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
CO5580725A2 (es) Herbicidas selectivos a base de tien-3-ilsulfonilamino (tio)-carbonil-triazolin(tio)onas substituidas y protectores
MXPA02012442A (es) Inhibidores de proteasa.
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal